Target
SGLT2
5 abstracts
Abstract
The effect of sodium glucose cotransporter-2 inhibitors on mortality and cardiovascular outcomes of patients with prostate cancer receiving luteinizing hormone releasing hormone agonists.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Unity Hospital, Rochester Regional Health System, Rochester, NY, Mount Auburn Hospital,
Abstract
Novel protein drug conjugate ANXV-chemo and cytotoxic and anti-proliferative effects against human triple-negative breast cancer in vitro.Org: Annexin Pharmaceuticals AB (publ), Truly Labs AB, ALMIR Conseil,
Abstract
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.Org: Division of Cardiology, Naples, Italy, Division of Cardiology, Azienda USL Toscana Nord-Ovest, Versilia Hospital, Lido Di Camaiore, Italy, Servizi Cardiologici Integrati, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, Sperimentazione Animale, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy, Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy,
Abstract
The impact of sodium-glucose cotransporter-2 inhibitors on the outcome of patients with colorectal adenocarcinoma.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, National Taiwan University Hospital Yunlin Branch, Taipei, Taiwan,
Abstract
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.Org: University of Miami/Jackson Memorial Hospital, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Caris Life Sciences, Irving, TX, Jackson Memorial Hospital/ University of Miami, Lombardi Comprehensive Cancer Center, Georgetown University,